Drug-Linker Conjugates for ADC

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

Drug-Linker Conjugates for ADC

The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.

The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.

Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.

Drug-Linker Conjugates for ADC related products

Cat No.	Product Name	CAS No.	Product Description
V54782	DL-01	2821770-49-2	DL-01 is an ADC active molecule-linker conjugate (drug-linker conjugates for ADC) that can be used for the synthesis of ADC.
V86048	DL-01 formic	2964513-44-6
V100176	DM1-MCC-PEG3-Biotin	2183472-94-6	DM1-MCC-PEG3-biotin is an ADC drug-linker conjugate.
V105321	DM21-L-G	2243689-87-2	DM21-LG is an ADC drug-linker conjugate that can be used to synthesize ADC molecules.
V54773	DM4-SMCC	1228105-52-9	DM4-SMCC is an antibody-linker conjugate for ADC with anti-tumor activity.
V54772	DM4-SPDP	2245698-48-8	DM4-SPDP is made up of linker SPDP and toxic molecule DM4, and may be utilized to prepare antibody-drug-conjugates/ADCss.
V88397	DMBA-SIL-Mal-MMAE	2923885-49-6	DMBA-SIL-Mal-MMAE is a cytotoxic linker used to prepare antibody-drug conjugates (ADCs) with potent anti-tumor activity.
V88394	EB-PSMA-617	2250333-97-0	EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy.
V88398	Fmoc-GGFG-DXd	1599440-11-5	Fmoc-GGFG-DXd is a part of the antibody-conjugated active molecule ADC (drug-linker conjugate for ADC).
V79474	Fmoc-Gly3-VC-PAB-MMAE		Fmoc-Gly3-VC-PAB-MMAE is an ADC drug-linker conjugates (Drug-Linker Conjugates for ADC).
V101678	Fmoc-NMe-Val-Val-Dil-Dap-OH	1352202-13-1	Fmoc-NMe-Val-Val-Dil-Dap-OH is an intermediate for preparing drug-linker conjugate MC-MMAF and can be used to synthesize ADC molecules.
V77005	Fmoc-Val-Cit-PAB-DuocarmycinTM		Fmoc-Val-Cit-PAB-Duocarmycin TM is an antibody-linker conjugate for ADC, which is made up of anti-tumor antibiotic Duocarmycin TM and Fmoc-Val-Cit-PAB.
V54796	Fmoc-VAP-MMAE	1912408-91-3	Fmoc-VAP-MMAE is an ADC drug-linker conjugate.
V85444	G3-VC-PAB-DMEA-Duocarmycin DM	2415664-00-3
V53016	GGFG-amide-glycol-amide-Exatecan	2866301-18-8	GGFG-amide-glycol-amide-Exatecan (Intermediate 2) is an Exatecan analogue that may be utilized in the preparation /synthesis of antibody drug conjugates (ADCs).
V53401	GGFG-Eribulin	2841688-66-0	GGFG-Eribulin (Compound GGFG) is an ADC-Drug-Linker Conjugates for ADC.
V92069	GGFG-PAB-Exatecan	251459-32-2	GGFG-PAB-Exatecan consists of the toxin molecule Exatecan and the linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules.
V103415	GGFG-PAB-Exatecan TFA		GGFG-PAB-Exatecan TFA consists of the toxin molecule Exatecan and the linker GGFG-PAB and can be used as a drug-linker conjugate for the synthesis of ADC molecules.
V79577	GGGDTDTC-Mc-vc-PAB-MMAE		GGGDTDTC-Mc-vc-PAB-MMAE is a drug-linker conjugate of ADC containing the tubulin inhibitor Monomethyl auristatin E (MMAE).
V53073	Glucocorticoid receptor agonist-1 Ala-Ala-Mal	2166376-51-6	Glucocorticoid receptor agonist-1 Ala-Ala-Mal (compound 88) is a glucocorticoid and a glucocorticoid receptor agonist.